Llwytho...

Resistant mutations in CML and Ph(+)ALL – role of ponatinib

In 2012, ponatinib (Iclusig(®)), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Miller, Geoffrey D, Bruno, Benjamin J, Lim, Carol S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2014
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208348/
https://ncbi.nlm.nih.gov/pubmed/25349473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S50734
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!